ArticleInternational journal of general medicine2026
Coagulation Activation Markers Associate with Early Neurological Function and Infarct Volume in Acute Ischemic Stroke.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The state of the coagulation-fibrinolysis system plays a pivotal role in thrombosis; however, its significance in guiding early revascularization for ischemic stroke remains inadequately understood. Objective: To explore the correlation between coagulation activation markers and early neurological function and infarction volume in acute ischemic stroke (AIS), and to evaluate their predictive value for stroke severity. Methods: This retrospective cohort study enrolled 135 patients with acute ischemic stroke. Participants were stratified into two groups based on admission National Institutes of Health Stroke Scale (NIHSS)scores: mild stroke group (NIHSS≤3, n=95) and moderate-to-severe stroke group (NIHSS>3, n=40). Five coagulation activation markers were quantified: thrombomodulin (TM), thrombin-antithrombin complex (TAT), plasmin-α2 plasmin inhibitor complex (PIC), tissue plasminogen activator-inhibitor complex (t-PAIC), and D-dimer. The associations between these biomarkers and stroke severity were evaluated using logistic regression models and receiver-operating characteristic (ROC) curve analyses. Infarct volume and its spatial distribution across distinct brain regions were quantified using dedicated neuroimaging software. Subsequently, the correlation between the five coagulation markers and both total infarct volume and region-specific infarction volumes were assessed. Results: Plasma levels of TAT, t-PAIC, and D-dimer were significantly elevated in the moderate-to-severe stroke group compared to the mild stroke group (p<0.05). Multivariate logistic regression analysis identified D-dimer as an independent risk factor for moderate-to-severe stroke (OR=1.002,95% CI:1.000-1.004). The area under the curve (AUC) values for TAT, t-PAIC, and D-dimer in predicting moderate-to-severe stroke were 0.62,0.63, and 0.59, respectively. The combined predictive model achieved an AUC of 0.67. Furthermore, within the moderate-to-severe stroke group, TAT levels demonstrated a positive correlation with anterior circulation cortical infarction volume (R=0.61, p<0.05). Additionally, D-dimer levels exhibited positive correlations with both total infarct volume and anterior circulation cortical infarction volume (R=0.74, p<0.05; R=0.79, p<0.05). Conclusion: TAT, t-PAIC and D-dimer serve as predictors for the severity of acute ischemic stroke, and can be used as a simple and rapid auxiliary tool combined with imaging evaluation to provide synergistic guidance for clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.